Literature DB >> 32108482

Spatiotemporal Proteomics Reveals the Molecular Consequences of Hormone Treatment in a Mouse Model of Lower Urinary Tract Dysfunction.

Samuel Thomas1, Ling Hao2, Kellen DeLaney3, Dalton McLean4, Laura Steinke2, Paul C Marker2, Chad M Vezina1,5,6, Lingjun Li1,2,3, William A Ricke1,2,4,5.   

Abstract

Benign prostatic hyperplasia and related lower urinary tract symptoms remain common, costly, and impactful issues for aging males. The etiology and pathogenesis are multifactorial and include steroid hormone changes and inflammation. Noninvasive markers could one day inform personalized medicine, but interindividual variation and lack of healthy age-matched controls hamper research. Experimental models are appealing for insight into disease mechanisms. Here, we present a spatiotemporal proteomics study in a mouse model of hormone-induced urinary dysfunction. Urine samples were collected noninvasively across time: before, during, and after disease onset. A microcomputed tomography analysis implicated the prostate as a spatially relevant contributor to bladder outlet obstruction. Prostates were collected after disease onset and compared with control mice. Notable changes in urine include proteins representing oxidative stress defense and acute phase inflammatory response processes. In the prostate, hormone treatment led to perturbations related to an oxidative stress response and H2O2 metabolism. Several protein changes coincided in both urine and the prostate tissue, including glutathione peroxidase 3, glutathione hydrolase 1 proenzyme, and vitamin D-binding protein. This study supports the concept of noninvasive urinary biomarkers for prostate disease diagnostics. Oxidative stress and acute phase inflammatory processes were identified as key consequences of hormone-induced bladder outlet obstruction. Future research into antioxidants and anti-inflammatories in prostate diseases appears promising.

Entities:  

Keywords:  endocrine disruption; lower urinary tract symptoms; prostate; proteomics; spatiotemporal; urine

Mesh:

Substances:

Year:  2020        PMID: 32108482      PMCID: PMC7339119          DOI: 10.1021/acs.jproteome.9b00451

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  43 in total

Review 1.  Androgens and estrogens in benign prostatic hyperplasia: past, present and future.

Authors:  Tristan M Nicholson; William A Ricke
Journal:  Differentiation       Date:  2011-05-26       Impact factor: 3.880

Review 2.  Prostatic fibrosis, lower urinary tract symptoms, and BPH.

Authors:  Jose A Rodriguez-Nieves; Jill A Macoska
Journal:  Nat Rev Urol       Date:  2013-07-16       Impact factor: 14.432

Review 3.  Oxidative stress in benign prostatic hyperplasia: a systematic review.

Authors:  Paola Lucia Minciullo; Antonino Inferrera; Michele Navarra; Gioacchino Calapai; Carlo Magno; Sebastiano Gangemi
Journal:  Urol Int       Date:  2014-12-05       Impact factor: 2.089

4.  Increased endogenous estrogen synthesis leads to the sequential induction of prostatic inflammation (prostatitis) and prostatic pre-malignancy.

Authors:  Stuart J Ellem; Hong Wang; Matti Poutanen; Gail P Risbridger
Journal:  Am J Pathol       Date:  2009-08-21       Impact factor: 4.307

5.  Hyperestrogenism and low serum testosterone-17β-estradiol ratio are associated with non-bacterial male accessory gland inflammation.

Authors:  Rosita A Condorelli; Aldo E Calogero; Sandro La Vignera
Journal:  Int J Immunopathol Pharmacol       Date:  2016-04-18       Impact factor: 3.219

6.  The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial.

Authors:  J Curtis Nickel; Claus G Roehrborn; Michael P O'Leary; David G Bostwick; Matthew C Somerville; Roger S Rittmaster
Journal:  Eur Urol       Date:  2007-11-20       Impact factor: 20.096

7.  Intraprostatic lymphocyte profiles in aged wistar rats with estradiol induced prostate inflammation.

Authors:  Eugene V Vykhovanets; Martin I Resnick; Susan Ruth Marengo
Journal:  J Urol       Date:  2006-04       Impact factor: 7.450

8.  Effect of the phytotherapeutic agent Eviprostat on 17beta-estradiol-induced nonbacterial inflammation in the rat prostate.

Authors:  Michiko Oka; Makoto Ueda; Tatsuya Oyama; Junko Kyotani; Mitsushi Tanaka
Journal:  Prostate       Date:  2009-09-15       Impact factor: 4.104

9.  Association of perfluoroalkyl substances exposure with reproductive hormone levels in adolescents: By sex status.

Authors:  Yang Zhou; Li-Wen Hu; Zhengmin Min Qian; Jen-Jen Chang; Chris King; Gunther Paul; Shao Lin; Pau-Chung Chen; Yungling Leo Lee; Guang-Hui Dong
Journal:  Environ Int       Date:  2016-05-31       Impact factor: 9.621

10.  Serum sex steroid hormones and lower urinary tract symptoms in Third National Health and Nutrition Examination Survey (NHANES III).

Authors:  Sabine Rohrmann; William G Nelson; Nader Rifai; Norma Kanarek; Shehzad Basaria; Konstantinos K Tsilidis; Ellen Smit; Edward Giovannucci; Elizabeth A Platz
Journal:  Urology       Date:  2007-04       Impact factor: 2.649

View more
  5 in total

1.  Increased COX-1 expression in benign prostate epithelial cells is triggered by mitochondrial dysfunction.

Authors:  Chandler N Hudson; Kai He; Laura E Pascal; Teresa Liu; Livianna K Myklebust; Rajiv Dhir; Pooja Srivastava; Naoki Yoshimura; Zhou Wang; William A Ricke; Donald B DeFranco
Journal:  Am J Clin Exp Urol       Date:  2022-08-15

2.  Bisphenol-A analogs induce lower urinary tract dysfunction in male mice.

Authors:  J L Nguyen; E A Ricke; T T Liu; R Gerona; L MacGillivray; Z Wang; B G Timms; D E Bjorling; F S Vom Saal; W A Ricke
Journal:  Biochem Pharmacol       Date:  2022-01-01       Impact factor: 6.100

3.  In utero and lactational 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) exposure exacerbates urinary dysfunction in hormone-treated C57BL/6J mice through a non-malignant mechanism involving proteomic changes in the prostate that differ from those elicited by testosterone and estradiol.

Authors:  Anne E Turco; Samuel Thomas; LaTasha K Crawford; Weiping Tang; Richard E Peterson; Lingjun Li; William A Ricke; Chad M Vezina
Journal:  Am J Clin Exp Urol       Date:  2020-02-25

4.  Urinary Metabolomic and Proteomic Analyses in a Mouse Model of Prostatic Inflammation.

Authors:  Pingli Wei; Ling Hao; Fengfei Ma; Qing Yu; Amanda Rae Buchberger; Sanghee Lee; Wade Bushman; Lingjun Li
Journal:  Urine (Amst)       Date:  2020-05-27

5.  Prostate-Specific Deletion of Cdh1 Induces Murine Prostatic Inflammation and Bladder Overactivity.

Authors:  Laura E Pascal; Shinsuke Mizoguchi; Wei Chen; Lora H Rigatti; Taro Igarashi; Rajiv Dhir; Pradeep Tyagi; Zeyu Wu; Zhenyu Yang; William C de Groat; Donald B DeFranco; Naoki Yoshimura; Zhou Wang
Journal:  Endocrinology       Date:  2021-01-01       Impact factor: 5.051

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.